Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using modified T cells in which TRAC genes are inactivated using a Zinc-finger nuclease (ZFN). The ZFN may include a first zinc finger protein (ZFP) that binds a first target site in a T-cell receptor alpha constant (TRAC) gene and a second ZFP that binds a second target site in the TRAC gene.

Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.

Abstract: A method for managing a Massive Multiple Input Multiple Output (M-MIMO) base station is disclosed. The method comprises receiving from a neighbour base station a notification of load conditions at the neighbour base station (110) and obtaining measurements on communication resources associated with the neighbour base station (120). The method further comprises determining whether there exists within a spatial distribution of traffic served by the neighbour base station a region having a concentration of traffic which is above a threshold level (130), and, if such a region exists, and if a condition for load transfer from the neighbour base station is fulfilled, causing at least one reference signal transmitted by the M-MIMO base station to be transmitted towards the determined region with a signal strength sufficient to trigger handover of a device in the determined region to the M-MIMO base station (160).

Abstract: In order to enable a UE receiving a narrowband signal transmitted using in-band resources to use the LTE reference signals to assist the UE in receiving the narrowband signal using an in-band deployment, a phase rotation employed by the base station may be fixed relative to a known reference position in time. An apparatus for wireless communication at a base station may determine a phase offset for a narrowband signal for transmission using wideband resources, the phase offset having a relationship to a reference point in time and transmit the narrowband signal using the determined phase offset. An apparatus for wireless communication at a UE may receive a narrowband signal having a frequency location within a wideband signal and rotate a symbol of the wideband signal by a per symbol phase offset having a relationship of the phase offset to a reference point in time.

Abstract: The present invention relates to the technical field of spacesuit performance tests, and in particular to a robot for testing lower limb performance of a spacesuit, comprising a pressure maintaining box, an air circulation component, an air cooling unit, heat radiating hose components and two mechanical legs.

Abstract: Various embodiments are directed to an electrochemical vinyl chloride sensor configured to detect a volume of vinyl chloride present within the volume of ambient gas. The electrochemical vinyl chloride sensor comprises a housing comprising an opening configured to receive a volume of ambient gas and an interior reservoir fluidly connected to the opening; and a plurality of electrodes fixedly disposed within the interior reservoir of the housing. The plurality of electrodes comprises a sensing electrode, a counter electrode, and a reference electrode, at least one of which comprises a catalytic material having an amorphous structure. A bias voltage of at least approximately less than 300 mV (e.g., 200 mV) applied between the sensing electrode and the reference electrode. The plurality of electrodes comprises a three-electrode stack configured such that the counter electrode is disposed between the sensing electrode and the reference electrode.

Abstract: Systems and methods for determining the concentration of a second target gas while in the presence of a first target gas. A method may comprise operating a first sensor (202, 302) under a first operating condition, wherein the first sensor (202, 302) is part of a sensor assembly (200); operating a second sensor (204, 304) under a second operating condition, wherein the second sensor (204, 304) is part of the sensor assembly (200), and wherein the second operating condition is different from the first operating condition; detecting at least one target gas by the first sensor (202, 302); detecting at least one target gas by the second sensor (204, 304); processing a signal output from the first sensor (202, 302) with a signal output from the second sensor (204, 304); and determining a concentration of at least one of the first target gas and second target gas based on the processed output signals.

Abstract: In one embodiment, a computing system may generate and display a virtual reality environment to a user. The computing system may determine a head pose of the user based on headset tracking data associated with a headset worn by the user. The computing system may determine a hand pose of the user based on hand tracking data associated with a device held or worn by a hand of the user. The computing system may access scene information associated with the displayed virtual reality environment. The computing system may determine a predicted focal point of the user within the virtual reality environment by processing the head pose, the hand pose, and the scene information using a machine-learning model.

Abstract: Compositions and methods for enhancing T cell response which increases the efficacy of CAR T cell therapy for treating cancer are described. Embodiments include a modified cell comprising an isolated nucleic acid comprising a first nucleic acid and a second nucleic acid, the first nucleic acid encoding a chimeric antigen receptor (CAR), the second nucleic acid encoding a therapeutic agent comprising at least one of IFN-?, IL-2, IL-6, IL-7, IL-15, IL-17, and IL-23. The modified cell expresses and secretes the therapeutic agent.

Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using modified T cells in which TRAC genes are inactivated using a Zinc-finger nuclease (ZFN). The ZFN may include a first zinc finger protein (ZFP) that binds a first target site in a T-cell receptor alpha constant (TRAC) gene and a second ZFP that binds a second target site in the TRAC gene.

Abstract: The present disclosure relates to compositions and methods for enhancing NK cell response and/or maintenance in vivo and/or in vitro. For example, a method of enhancing NK cell-based therapy comprises administering a mixed population of NK cells comprising modified NK cells comprising a first chimeric antigen receptor (CAR) and modified NK cells comprising a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.

Abstract: Methods, systems, and devices for wireless communications are described. A UE may transmit a capability message to a base station. The capability message may indicate a capability of the UE to monitor a defined number of resources across a set of component carriers (CCs) within a time period. The resources may be channel measurement resources (CMRs) or interference measurement resources (IMRs) for signal to interference plus noise measurement, reference signal (RS) resources for channel state information (CSI) measurement, beam failure detection (BFD), reference signal receive power (RSRP) measurement, link quality monitoring, or different active beams. Based on the capability of the UE, the base station may transmit a monitoring configuration to the UE that indicates a set of resources or active beams for the UE to monitor in the set of CCs. The UE may monitor the defined resources or beams received in the monitoring configuration from the base station.

Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, in a method of in vivo cell expansion, the method comprises administering an effective amount of cells comprising an antigen binding molecule to a subject; and administering an effective amount of presenting cells expressing a solid tumor antigen that the binding molecule binds.

Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, a method of enhancing T cell-based therapy comprises administering genetically modified T cells comprising a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.

Abstract: The present disclosure relates to compositions and methods of enhancing expansion of a population of cells targeting a solid tumor and/or enhancing treatment on the solid tumor using the population of cells. For example, the method comprises administering an effective amount of a composition comprising a first population of cells targeting a WBC antigen and a second population of cells targeting the solid tumor to a subject having the solid tumor; and allowing the second population of cells to expand, wherein there are at least as many or more of the second population of cells targeting the solid tumor than the first population of cells targeting the WBC antigen.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may transmit a communication that identifies one or more UE capability parameters for at least one of sounding reference signal reference signal received power measurement or cross-link interference (CLI) received signal strength indication measurement. The UE may receive a CLI measurement configuration that is based at least in part on the one or more UE capability parameters. Numerous other aspects are provided.

Abstract: Compositions and methods for enhancing T cell response which increases the efficacy of CAR T cell therapy for treating cancer are described. Embodiments include a modified cell comprising an isolated nucleic acid comprising a first nucleic acid and a second nucleic acid, the first nucleic acid encoding a chimeric antigen receptor (CAR), the second nucleic acid encoding a therapeutic agent comprising at least one of IFN-?, IL-2, IL-6, IL-7, IL-15, IL-17, and IL-23. The modified cell expresses and secretes the therapeutic agent.

Abstract: A method and an apparatus are provided. Distribution information in a first attribute dimension is acquired from a persona data collection of users who use a network service. The persona data collection includes persona data sets corresponding to the users. An evaluation data collection to match the distribution information in the first attribute dimension is extracted from a sample data collection that is collected from sample users. The sample data collection includes sample data sets corresponding to the sample users. Further, a level of accuracy of the persona data collection in a second attribute dimension is determined based on the evaluation data collection in the second attribute dimension.

Abstract: The present disclosure describes a method of producing T cells exhibiting an enhanced memory T cell phenotype, the method comprising: modulating a population of T cells to enhance the expression and/or function of high mobility group protein Y (HMGY). In embodiments, the method may include introducing a polynucleotide encoding HMGY into a population of T cells, wherein expression of HMGY is higher in the population of T cells as compared to a population of T cells that are not introduced with the polynucleotide, and the memory T cell phenotype of the population of T cells is enhanced as compared to T cells that are not introduced with the polynucleotide. In embodiments, the method can also include introducing a polynucleotide encoding one or more genes associated with HMGY, for example, upstream or downstream of the signaling pathway associated with HMGY and/or a transcription factor associated with HMGY.

Abstract: A food processor and an electric motor for a food processor. The electric motor includes: a stator core having a ring-shaped stator yoke and a plurality of stator teeth provided at an inner peripheral face of the stator yoke, two adjacent stator teeth defining a stator slot there between, the plurality of the stator teeth defining a stator hole coaxial with the stator yoke, and an outer contour of a radial section of the stator yoke being substantially circular and having a maximum radial dimension D; and a rotor core rotatably provided in the stator hole and coaxial with the stator hole, the rotor core having a maximum radial dimension d, in which 0.4?d/D?0.55.